Regulus Therapeutics
$0.75649876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.7564
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.017 (-2.20%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours
Why Robinhood?
You can buy or sell RGLS and other stocks, options, ETFs, and crypto commission-free!
About RGLS
Regulus Therapeutics Inc. Common Stock, also called Regulus Therapeutics, is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Read More Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
Employees
24
Headquarters
San Diego, California
Founded
—
Market Cap
16.12M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
132.64K
High Today
$0.7999
Low Today
$0.7411
Open Price
$0.7762
Volume
66.09K
52 Week High
$1.65
52 Week Low
$0.5026
Collections
RGLS Earnings
-$1.25
-$0.88
-$0.50
-$0.13
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Mar 16, After Hours